Based in New Haven, CT, Modifi Bio is a leader in direct DNA modification developing novel therapeutics by uniquely targeting tumor-associated DNA repair defects. Aiming to improve the standard of cancer therapy and patient care, the Modifi Bio team includes world-renowned scientists, clinicians and experienced biotech entrepreneurs with deep expertise in synthetic chemistry, DNA repair, and translational research in oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/16/23 | $4,300,000 | Seed |
Advantage Capital Brightedge Connecticut Innovations HighCape Partners Pathway Bioventures Sontag Family Trust | undisclosed |
